In another Italian retrospective study, all consecutive advanced NSCLC patients using ICIs (anti-PD-1, n = 205; anti-PD-L1, n = 77; anti-CTLA4 or combination ICI therapy, n = 8) between April 2013 and March 2019 were analyzed [37]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.